1 ; OF MUCUS PHYSICAL WHAT ARE PATIENTS THE PROPERTIES FROM CALCIUM EFFECTS ON CF
2 ; OF RESPIRATORY MUCUS AND CAN TRACT THE IN HYPERSECRETION INFECTION SUBMUCOSAL DISTINGUISH BETWEEN ONE EFFECTS GLANDS ON CF
3 ; OF HOW GLYCOPROTEINS THOSE ARE PATIENTS SUBJECTS FROM DIFFERENT NORMAL SALIVARY CF
4 ; OF RESPIRATORY WHAT LIPID THE SECRETIONS COMPOSITION CF IS
5 ; ABNORMAL MUCUS CF IS
6 ; OF OTHER CF ELASTICITY AGENTS WHAT WATER THERAPEUTIC PHYSICAL BRONCHIAL PATIENTS THE EFFECT SPUTUM SECRETIONS PROPERTIES VISCOSITY FROM ON OR IS
7 ; COMPARED MUCUS GLYCOPROTEINS THOSE ARE DEGRADED PATIENTS IN TO DIFFERENTLY SUBJECTS AS FROM NORMAL CF
8 ; RESPIRATORY DIFFERENCES WHAT HISTOCHEMICAL EPITHELIA AND HAVE NORMAL BETWEEN DESCRIBED CF BEEN
9 ; ASSOCIATION DISEASE LIVER WHAT METABOLISM AND THE IN CIRRHOSIS BETWEEN VITAMIN CF IS
10 ; OF CF WHAT WITH PATIENTS THE ROLE IN VITAMIN THERAPY IS
11 ; WHAT AND DIFFERENCE THE SYNDROME PLUG BETWEEN ILEUS MECONIUM IS
12 ; OF AMINO WHAT ACID PATIENTS IN THE TRANSPORT HAVE SMALL BOWEL ABNORMALITIES DESCRIBED CF BEEN
13 ; OF PANCREATITIS WHAT ARE PATIENTS THE IN FEATURES CLINICAL BIOCHEMICAL CF OR
14 ; OF PERFORMED EVALUATION TESTS WHAT PANCREATIC EXOCRINE WITH CAN PATIENTS THE IN FOR BE FUNCTION CF NON-INVASIVE
15 ; OF WHAT ARE HEPATIC THE COMPLICATIONS CF OR MANIFESTATIONS
16 ; OF NEONATAL GASTROINTESTINAL LIVER WHAT ARE AFTER AND THE COMPLICATIONS PERIOD EXCLUDE MECONIUM CF ILEUS DISEASE
17 ; OF CF MOST WHAT EFFECTIVE PANCREATIC ENZYME PATIENTS TREATMENT THE IN FOR REGIMEN USE SUPPLEMENTS IS
18 ; OF THERAPEUTIC WITH BENEFIT SUPPLEMENTATION BILE TO PATIENTS SALTS DIETARY CF IS
19 ; OF WHAT PANCREATIC ENZYME PATIENTS IN COMPLICATIONS REPORTED HAVE THERAPY CF BEEN
20 ; OF WHAT WITH ACID PATIENTS TREATMENT THE EFFECT FATTY ESSENTIAL CF SUPPLEMENTS IS
21 ; DOES PANCREATIC INSUFFICIENCY PATIENTS IN TO ABSORB IRON THEIR AFFECT ABILITY CF OR METABOLIZE
22 ; OF NON-CAUCASIAN WHAT THE IN POPULATIONS CF FREQUENCY IS
23 ; FOUND ASSOCIATION CF CONDITIONS WHAT WITH HEREDITARY IN DISEASES HAVE CONGENITAL OR BEEN
24 ; OF WHAT MANIFESTED ARE PATIENTS INCOMPLETELY THE IN WHOM CHARACTERISTICS CF IS
25 ; THAN WHAT BASIS EVIDENCE THE MORE GENE FOR THERE GENETIC INVOLVES THAT ONE CF IS
26 ; WHAT ADVANTAGE IN THE HETEROZYGOTE CF IS
27 ; OF MANIFESTATIONS PAIRS WHAT BOTH SIBLING THE IN WHOM HAVE CONCORDANCE CLINICAL BIOCHEMICAL CF OR IS
28 ; OF WHAT INCIDENCE THE IN MALE FERTILITY CF IS
29 ; OF REPRODUCTIVE IS WHAT SYSTEM THE IN MALE FEMALE CF OR PATHOLOGY
30 ; OF WHAT RESULTS CHILDREN WITH ARE THE GENETIC FAMILIES COUNSELING CF
31 ; OF MAJOR WHAT ARE PATIENTS AND THE SOCIAL FAMILIES THEIR EFFECTS PSYCHOLOGICAL CF OR ON
32 ; PRESCRIBED WHAT WITH PATIENTS IN INFLUENCE FACTORS COMPLIANCE THERAPY CF
33 ; SWEAT CONDITIONS WHAT TESTS TO ERRONEOUS FACTORS OR LEAD
34 ; OF OTHER CLASSICAL TECHNIQUES AVAILABLE CHLORIDE ARE THE GIBSON-COOKE ALTERNATIVE RELATIVE SWEAT WHAT WITH TEST TITRIMETRIC TESTING THEIR THAN PILOCARPINE IONTOPHORESIS AND ADVANTAGES FOR ANALYSIS QUANTITATIVE DISADVANTAGES
35 ; FOUND ANY SWEAT TESTS TO CONSISTENTLY PATIENT HAVE NORMAL HAS CF BEEN
36 ; OF SWEAT WHAT PATIENTS THE IN POTASSIUM FROM CONCENTRATION CF IS
37 ; OF AVAILABLE TECHNIQUES SCREENING WHAT RESULTS TESTS ARE AND TO FOR INFANTS ERRONEOUS THESE FACTORS CONTRIBUTE NEWBORN CF
38 ; CAN BE PRENATALLY CF DIAGNOSED
39 ; HOW IDENTIFIED FOR HETEROZYGOTES MAY BE CF
40 ; THAN OTHER NEONATAL SWEAT TECHNIQUES WHAT OF TEST USEFUL THE FOR BEYOND DIAGNOSIS MAY PERIOD BE CF
41 ; METABOLISM PATIENTS IN NORMAL CF VITAMIN IS
42 ; OF CF WHAT METABOLISM PATIENTS IN SECRETION ABNORMALITIES OCCUR OR INSULIN
43 ; IS SODIUM CHLORIDE ABNORMAL IN SALT TRANSPORT/PERMEABILITY CF AND/OR
44 ; DIFFERENCES WHAT ARE PATIENTS AND NON-CF FIBROBLASTS THERE FROM ENZYMATIC BETWEEN STRUCTURAL CF OR
45 ; OF WHAT METABOLISM PATIENTS IN PROSTAGLANDIN HAVE ABNORMALITIES DESCRIBED CF BEEN
46 ; OF WHAT ARE AND PATIENTS THE PROPERTIES FROM ACTIVITY CF ENZYMES GALACTOSYLTRANSFERASE
47 ; OR OF DIFFERENCES WHAT METABOLISM AND PATIENTS IN THE SUBJECTS HAVE HORMONES NORMAL BETWEEN DESCRIBED CF FUNCTION BEEN
48 ; AT PATIENTS GROW FIBROBLASTS FROM NORMAL RATE DO CF
49 ; METABOLISM METHYLATION PATIENTS IN RNA POLYAMINE NORMAL CF OR IS
50 ; OF DEFECTS WHAT METABOLISM NUCLEOTIDES CYCLIC PATIENTS IN THE HAVE SYNTHESIS DESCRIBED CF OR BEEN
51 ; ARE PATIENTS SECRETED ACTIVE CYSTIC DESCRIBED SOME CIRCULATING WHAT THOUGHT MOLECULES BIOLOGICALLY FACTORS HAVE PLAY OR UNIDENTIFIED IN TO ROLE PATHOGENETIC CF `` '' FIBROSIS BEEN
52 ; KNOWN PROLACTIN WHAT PATIENTS IN ABOUT CF IS
53 ; SECRETORY DOES PATIENTS COLONIZATION INFECTION PROTECT AGAINST BACTERIAL IGA CF OR
54 ; OF IS OR DISEASE WHAT PATIENTS THE TO IN LUNG HYPERSENSITIVITY CF RELATIONSHIP ALLERGY
55 ; ANTIPROTEASES OF LUNGS WHAT INTERACTIONS ARE AND PATIENTS THE IN ORIGIN PROTEASES BETWEEN BACTERIAL CF OR ENDOGENOUS
56 ; WHAT AND PULMONARY PATIENTS NUTRITION THE HOST DEFENSES IN INFECTION AGAINST BETWEEN BACTERIAL CF RELATIONSHIP IS
57 ; OF CIRCULATING WHAT PATIENTS PSEUDOMONAS THE ROLE TO PATHOPHYSIOLOGIC AERUGINOSA IN ANTIBODIES CF IS
58 ; WHAT PULMONARY PATIENTS THE TO IN INFECTION IMMUNOLOGIC RESPONSE CF IS
59 ; FOUND WHAT PATIENTS IN IMMUNOLOGIC HAVE ABNORMALITIES CF BEEN
60 ; OF WHAT ARE PULMONARY THE CIRCULATION EFFECTS CF ON
61 ; RESPIRATORY OF MUCOCILIARY CLEARANCE PATIENTS TRACT IN THE DEFECT THERE TRANSPORT CF IS
62 ; OF WHAT ARE PATIENTS THE IN LUNG FEATURES CLINICAL CF DISEASE
63 ; OF WHAT ARE AIRWAY PATIENTS THE IN CHARACTERISTICS MICROSCOPIC BIOCHEMICAL INFLAMMATION CF OR
64 ; THAN HOW DOES WITH PATIENTS IN DAY LUNG PERIODS GREATER FUNCTION CF CHANGE TIME
65 ; OF WHAT ARE PULMONARY PATIENTS THE IN ABNORMALITIES FUNCTION CF
66 ; OF WHAT ARE PATIENTS THE IN LUNG FEATURES PATHOLOGIC CF DISEASE
67 ; OF RESPIRATORY WHAT HAD FAILURE PATIENTS AN THE WHO EPISODE FOR HAVE PROGNOSIS IS
68 ; OF WHAT ARE PATIENTS THE IN BRONCHODILATORS EFFECTS CF
69 ; WHAT TREAT PATIENTS THE TO IN WAY BEST PNEUMOTHORAX CF IS
70 ; OF WHAT AND PATIENTS TREATMENT THE IN FOR HEMOPTYSIS PROGNOSIS CF IS
71 ; WHAT WITH AND THE FOR INFANTS WHEEZING PROGNOSIS CYSTIC FIBROSIS IS
72 ; WHAT PATIENTS TREATMENT THE IN FOR BEST NASAL POLYPS CF IS
73 ; HOW BRONCHIAL EFFECTIVE PATIENTS IN LAVAGE CF IS
74 ; OF RESPIRATORY WHAT RESULTS WITH FAILURE ARE PATIENTS THE VENTILATION IN MECHANICAL CF
75 ; AND/OR PULMONALE WHAT HYPERTENSION PULMONARY PATIENTS TREATMENT THE IN FOR COR BEST CF IS
76 ; OF PROGRAMS WHAT ARE PATIENTS TRAINING THE IN LUNG EFFECTS FUNCTION ON EXERCISE CF
77 ; OF TECHNIQUES CLEARANCE WHAT EFFECTIVE MUCUS LUNGS ARE PATIENTS IN PROMOTING THE FROM CF
78 ; OF OTHER ARE PATIENTS TREATMENT THE IE SPECIAL WHAT WITH PHARMACODYNAMICS OR IN TO FOR THERE ANTIBIOTICS DIFFERENT CONSIDERATIONS CF PECULIAR PROBLEMS
79 ; OF ADMINISTERED WHAT ORALLY PATIENTS TREATMENT THE ROLE IN ANTIBIOTICS CF IS
80 ; AMINOGLYCOSIDES THAN WHAT WITH EFFECTIVE ALONE EVIDENCE AND THE MORE SEMISYNTHETIC PENICILLINS EITHER THAT THERAPY COMBINATION IS
81 ; OF HOW MUCOLYTIC AGENTS EFFECTIVE ARE PATIENTS INHALATIONS IN THE TREATMENT CF
82 ; OF DISEASE WHAT PATIENTS TREATMENT THE ROLE IN LUNG AEROSOLS CF IS
83 ; OF DISEASE MACROPHAGES WHAT PHAGOCYTOSIS POLYMORPHONUCLEAR PATIENTS THE ROLE ALVEOLAR IN LUNG BY LEUKOCYTES BACTERIAL CF OR IS
84 ; INFLUENZAE WHAT AND PATIENTS PSEUDOMONAS THE IN HAEMOPHILUS AERUGINOSA BETWEEN CF RELATIONSHIP IS
85 ; EVER OTHER THAN ORGANS WHAT PATIENTS IN THE SO LUNG INFECTION IF DO CF DEVELOP
86 ; OF BACTERIA OTHER THAN INFLUENZAE WHAT DISEASE PATIENTS PSEUDOMONAS THE ROLE HAEMOPHILUS IN AERUGINOSA LUNG STAPHYLOCOCCUS AUREUS PATHOGENESIS CF OR IS
87 ; OF DISEASE WHAT PATIENTS THE ROLE IN LUNG PATHOGENESIS FUNGI CF IS
88 ; OF DISEASE WHAT VIRAL PATIENTS THE ROLE IN LUNG INFECTION CF IS
89 ; OF SPREAD OTHER OR FAMILY WHAT PATIENTS PSEUDOMONAS THE IN TO AERUGINOSA INDIVIDUALS SPECIFICALLY EPIDEMIOLOGY CF DO IS
90 ; OF STRAINS WHAT ARE MUCOID PSEUDOMONAS THE IN PATIENTS FOR RESPONSIBLE AERUGINOSA FACTORS CF APPEARANCE
91 ; OF OTHER THAN OR WHAT PANCREATIC EXOCRINE ARE INSUFFICIENCY THE LUNG UNUSUAL CF MANIFESTATIONS DISEASE
92 ; OF SURVIVAL WHAT WITH PATIENTS THE FOR PROGNOSIS CF IS
94 ; AVAILABLE WHAT ARE TO WHICH ANIMAL MODELS RELEVANT CF
95 ; OF FOUND STRUCTURE CF WHAT PATIENTS IN MUSCLE HAVE SKELETAL ABNORMALITIES FUNCTION OR BEEN
96 ; OF DISEASE INCIDENCE INCREASED PATIENTS AN PERIODONTAL IN PROBLEMS THERE DENTAL EG CARIES CF OR IS
97 ; CELLS OXYGEN ABNORMAL PATIENTS IN RED BLOOD TRANSPORT BY CF IS
98 ; OF WHAT ARE DEVELOPMENT AND THE SYSTEM CENTRAL EFFECTS BRAIN NERVOUS FUNCTION CF ON AND/OR
99 ; OF ARE PATIENTS IN THERE TASTE ABNORMALITIES CF
100 ; OF OSTEOARTHROPATHY WHAT INCIDENCE AND PATIENTS TREATMENT THE IN FOR HYPERTROPHIC CF IS